Literature DB >> 2528260

Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma.

V M Verallo-Rowell1, V Verallo, K Graupe, L Lopez-Villafuerte, M Garcia-Lopez.   

Abstract

Melasma is a macular hypermelanosis of the sun-exposed areas of the face and neck. The clinical efficacy of azelaic acid (20%) and hydroquinone creams (2%) in the treatment of this benign pigmentary disorder was compared in a randomized, double-blind study with 155 patients of Indo-Malay-Hispanic origin. The creams were applied twice daily. A broad spectrum sunscreen was used concomitantly. Over a period of 24 weeks, 73% of the azelaic acid patients, compared with 19% of the hydroquinone patients, had good to excellent overall results, as measured by the reduction of melasma pigmentary intensity and lesion size. Transient mild to moderate irritant reactions were initially seen with both test drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528260

Source DB:  PubMed          Journal:  Acta Derm Venereol Suppl (Stockh)        ISSN: 0365-8341


  17 in total

1.  Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color.

Authors:  Erica C Davis; Valerie D Callender
Journal:  J Clin Aesthet Dermatol       Date:  2010-07

2.  [Methods and means for pigmentation and depigmentation. Sense or nonsense?].

Authors:  V Hegyi; J Hegyi
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

Review 3.  Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 4.  Dermatology: how to manage facial hyperpigmentation in skin of colour.

Authors:  Siddiq Moolla; Yvette Miller-Monthrope
Journal:  Drugs Context       Date:  2022-05-31

Review 5.  Topical treatment strategies to manipulate human skin pigmentation.

Authors:  Inbal Rachmin; Stephen M Ostrowski; Qing Yu Weng; David E Fisher
Journal:  Adv Drug Deliv Rev       Date:  2020-02-21       Impact factor: 15.470

6.  Discovery of highly potent tyrosinase inhibitor, T1, with significant anti-melanogenesis ability by zebrafish in vivo assay and computational molecular modeling.

Authors:  Wang-Chuan Chen; Tien-Sheng Tseng; Nai-Wan Hsiao; Yun-Lian Lin; Zhi-Hong Wen; Chin-Chuan Tsai; Yu-Ching Lee; Hui-Hsiung Lin; Keng-Chang Tsai
Journal:  Sci Rep       Date:  2015-01-23       Impact factor: 4.379

7.  Evidence-based treatment for melasma: expert opinion and a review.

Authors:  Krupa Shankar; Kiran Godse; Sanjeev Aurangabadkar; Koushik Lahiri; Venkat Mysore; Anil Ganjoo; Maya Vedamurty; Malavika Kohli; Jaishree Sharad; Ganesh Kadhe; Pashmina Ahirrao; Varsha Narayanan; Salman Abdulrehman Motlekar
Journal:  Dermatol Ther (Heidelb)       Date:  2014-10-01

8.  Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential.

Authors:  Birendra Kumar Singh; Seok Hoon Park; Hyang-Bok Lee; Young-Aae Goo; Hyoung Shik Kim; Seung Hee Cho; Jeong Hun Lee; Ghe Whan Ahn; Jin Pyo Kim; Su Myoung Kang; Eun-Ki Kim
Journal:  Ann Dermatol       Date:  2016-09-30       Impact factor: 1.444

9.  Topical treatment of melasma.

Authors:  Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

10.  A Comparison of Low-Fluence 1064-nm Q-Switched Nd: YAG Laser with Topical 20% Azelaic Acid Cream and their Combination in Melasma in Indian Patients.

Authors:  Charu Bansal; Hira Naik; Hemanta K Kar; Amrita Chauhan
Journal:  J Cutan Aesthet Surg       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.